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The angiotensin-converting enzyme (ACE) regulates the levels of blood pressure 
through generation of angiotensin-II from angiotensin-I. It is of great importance to 
have a reliable and yet simple method for a quantitative determination ACE 
inhibitory peptides in whey of milk products. A rapid, simple, sensitive and accurate 
spectrophotometric kinetic method has been developed for determination of ACE 
inhibitory peptides, using competitive inhibition. Samples of dairy product from the 
market were used for the determination of ACE inhibitory peptides in whey. 
Holmquist’s kinetic method was used for determining ACE inhibitory activity in 
blood serum and Ronca-Testoni method was used for the determination of ACE 
inhibitory activity in whey. Enzymatic inhibition activity was determined using 0.8 
mmol/L FAPGG (N-[3-(Furyl) –Acryloyl]-L-Phenylalanyl Glycyl Glycyne) as the 
substrate in 50 mmol/L Tris buffer at pH 8.2 at 37
°C and a standard serum 
containing ACE. First, a solution of whey was mixed in a 1 to 10 ratio with serum 
(elevation) containing high ACE activity. The enzymatic activity was determined by 
monitoring the decrease in absorbance at 340 nm as result of hydrolysis of the 
substrate. The concentration of ACE inhibitory peptides was determined from a 
standard curve of inhibitor concentration versus percent of ACE inhibition. The 
study suggests that the method possesses good reproducibility and accuracy. The 
linear range enabled determination of high enzymatic activity of ACE and all ACE 
inhibitory peptides from dairy products act as competitive inhibitors. 
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INTRODUCTION 
 
The angiotensin-converting enzyme (ACE) regulates 
the levels of blood pressure levels (Inoue et al., 2011) 
through generation of angiotensin II from angiotensin I. It 
has been considered as a target for research on 
antihypertensive agents and a therapeutic approach for 
blood pressure management.  
Synthetic ACE inhibitors lead to development of 
adverse consequences, hence, low-cost, safer alternatives 
is being explored. ACE inhibitory activity have been 
reported for peptides from protein of animals’ origin, 
including casein (Miguel et al., 2009; Ayyash et al., 
2012), whey (Mullally et al., 1997), egg (Miguel and 
Aleixandre, 2006), soybean (Lo and Li-Chan, 2005) and 
chicken breast muscle (Saiga et al., 2006).  A research 
study (Lin et al., 2012) recommended ACE inhibitors 
derived from squid byproducts for developing anti-
hypertensive functional foods. The hydrolysate (HSSG-
III) was found as having a potent ACE inhibitory activity 
in vitro having an IC50 value of 0.33 mg/ml. After oral 
intake, the HSSG-III lowered the systolic and diastolic 
blood pressure in renovascular hypertensive rats.  
These authors developed a rapid, reproducible 
evaluation of ACE inhibition in various foods and 
developed an assay to screen inhibitors of ACE using 
high-throughput LC/SID-ESI-MS/MS. Several spectro-
photometric methods have been developed for 
determination of the enzymatic activity of the angiotensin-
converting enzyme (ACE), and are regularly used because 
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of their availability, simplicity and the high level of 
accuracy. The first developed method uses the substrate 
N-α-hipuryl-L-histidyl-L-leucine, synthesized on the 
analogy of the natural substrate A-I introduced by 
Cushman and Cheung (1971). The same method with 
minor modifications was used by Liberman (1975). The 
method is based on the determination of the released 
hipuric acid. Hayakari et al. (1984) introduced into the 
reaction 2, 4, 6-trichloro-s-triazin in 1, 4-dioksan which in 
the reaction with the hipuric acid gives colored 
compound. 
Holmquist  et al. (1979) have synthesized new 
substrate N-[3-(2-furil)-akriloil]-L-fenilalanil-glycyl-glycine 
(FAPGG) and have introduced, for the first time, a new 
continued kinetic method for determining the ACE 
activity in serum. With hydrolysis, the resulting product 
has a lower absorbance than the substrate at 345 nm, thus 
the resulting absorbance is negative and there is a drop in 
the absorbance level. The substrate is specific to ACE and 
has faster hydrolysis process than other used substrates. 
There are several developed methods using this substrate, 
from which several are adapted for usage in automatic 
analisators. The same method is applied in determining 
ACE inhibition in whey and other dairy products.  
The ACE enzyme is metalopeptidase that depends on 
zinc, which severs the S-terminal peptides of different 
oligopeptides. This enzyme has a broad range of 
substrates and contains two terminals for connecting with 
the substrate with variable affinity towards the substrates 
and/or the inhibitors (Cushman et al., 1973). The peptides 
may react as ACE inhibitors trough multiple different 
mechanisms. As first, the peptides may bond to the active 
side of the ACE without being hydrolyzed by the enzyme. 
These peptides are called real inhibitors. As second, the 
inhibitory peptides may be substrates to the ACE. These 
peptides are hydrolyzed by ACE, releasing new peptides, 
which may be more or less active inhibitors than the 
initial peptide. The peptides which are more active 
inhibitors after the decomposition from the ACE, are 
called prodrug-type inhibitors (Cheung et al., 1980). The 
less active peptides are called substrate-type inhibitors. 
Examples for real inhibitors may include LKP, IWH and 
IKP. LKPNM and IWHHT are examples for prodrug-type 
inhibitors. A great number of protein hydrolysates and 
peptides derived from different nutrients are known to 
present their activity as ACE inhibitors. There are a large 
number of hydrolysates and peptides that manifest ACE 
inhibitory activity. Hydrolysates from fermented milk, 
casein and whey proteins have shown in vitro ACE 
inhibitory activity, and/or in vivo antihypertensive 
activity, and have different amino acid profile and derive 
from whey protein and casein peptides with significant 
ACE inhibition. Hydrolysates derived with different 
enzymes and different source of protein have shown ACE 
inhibitory activity. From that can be concluded that the 
ACE inhibition can be induced by different peptides or a 
combination of peptides. The ACE inhibitory activity 
depends on the origin of the protein or peptide, and the 
enzyme used in the proteolysis.  
The most common factor for the ACE inhibitory 
activity is the small molecular mass of the ACE inhibitory 
peptides. The procedures implemented for in vivo studies 
for ACE inhibitory activity of peptides are not 
standardized. The quantity of ACE used in the procedures, 
and the type of ACE substrate are important for 
calculating the IC50 value (concentration of peptide 
required for lowering the ACE activity by 50%). Despite 
that, very often the concentration of ACE is not even 
mentioned. The difference in the conditions of the 
procedure may be a reason for the differences between 
IC50 values published for the same peptide. 
The objectives of this research were examination of 
the optimum conditions for application of the method for 
determining the activity of ACE in whey, examining the 
performance of the method in samples of standard serum, 
and determining in vitro ACE inhibition in milk samples 
from commercial dairy products.  
 
MATERIALS AND METHODS 
 
Random samples of dairy products were collected 
from retail shops for this study. The method for 
determining ACE inhibitory activity in serum as already 
described (Ronca-Testoni, 1983), was modified. The 
separation of the low molecular proteins and peptides 
from macromolecules proteins, casein and fat was 
conducted using centrifuge IEC (Micromax), having at 
20000 g. Fermentation process was monitored using pH-
meter (Hanna Instruments). Spectroscopic determination 
of total peptides and ACE inhibitory activity was 
conducted through spectrophotometer (Specol, 1200). 
 
Determining the enzymatic activity of ACE in whey: 
Enzymatic activity of ACE in a serum samples was 
determined (Ronca-Testoni, 1983). The substrate used was 
N-[3-(2-furil)-acryloil]-L-phenylalanine-glycyl-glycine 
(FAPGG, C20H21H3O6, Sigma Cat # 7131). The determi-
nation is based on the difference in absorbance of 
furanacryloil blocked tripeptide FAPGG and the product of 
the enzyme-catalyzed hydrolysis FAP at wavelength of 340 
nm. Gly-Gly is the result of hydrolyses of FAPGG and does 
not absorb light at these conditions which is evident from the 
following equation-1). As the hydrolysis product FAP has 
low absorbance at 340 nm the resulting change of the 
absorbance is negative: 
 
FAPGG ⎯ ⎯→ ⎯
ACE  FAP + Gly-Gly                 (Equation 1) 
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The following procedure was used for preparing buffer 
solution: a) tris buffer 0.2 mol/L (2 hydroxymethyl-1,3-
propanediol, Merck No 108382 MM=121,14 g/mol) was 
mixed with 24.23 g/L boiled and cooled deionized water to 
prepare standard buffer solution; b) hydrochloric acid 
solution (0.1 mol/L) was prepared;  c) the buffer solution was 
prepared using different ratios of a and b solutions; sodium 
chloride solution 300 mmol/L was added.  
Substrate solution (2 mmol/L) was prepared by 
dissolving 0.07988 g FAPGG (MM=399.4 g/mol in 100 
ml buffer solution. The primary solution was diluted with 
the buffer solution. Control serums for ACE (Sigma) were 
measured using the spectroscopic kinetic method (Specol 
1200) at 340 nm and 37
oC. 
The buffer solution comprised of: Tris buffer 50 
mmol/L pH 8,2 (37°S), 300 mmol/L chlorides: 25 ml tris 
buffer solution 0.2 mol/L, 20 ml 0.1 mol/L HCl and 10 ml 
3 mol/L NaCl solution. The measuring flask was filled up 
to 100 ml with deionized water. The substrate solution 
comprised of  0.8 mmol/L FAPGG: 0.032 g in 100 ml 50 
mmol/L Tris buffer solution pH 8.2.  
 
Determining serum ACE activity: Buffered substrate 
was added (2000 µL) along with 200 µL serum sample, 
into a 10 ml cuvette. The mixture was incubated for 5 
min. at 37°C. Тhe initial absorbance was read at 340 nm. 
Than after exactly 5 min. the drop in the absorbance level 
was recorded and the difference was calculated using 
equation 2. 
1000
1 1
) / ( ⋅
∆
⋅ ⋅ ⋅ ∆ =
ε t V
V
A L U ACE
s
t        (Equation 2) 
∆A- change in the absorbance after 5 min.; 
Vt   -total volume of the reaction mixture  
Vs  - volume of the serum sample  
t     - interval of measuring the change of the absorbance 
∆ε - differential molar absorbing coefficient FAPGG / 
FAP at 340 nm. 
 
The reaction mixture comprises of 0.8 mol/L 
FAPGG, 50 mmol/L tris buffer, 8.2 (37°C) pH, chlorides 
300 mmol/L, with addition of 100 µL serum in 2000 µL 
reaction mixture. The determinations were made at 340 
nm, 37
oC, and serum reagent ratio of 1:10, time of 
incubation 5 min, measuring interval 5 min, and 
calculations made with calibration factor. Commercial 
solutions for ACE (Sigma) were used. 
The kinetic curve of the dependence of the speed of 
the enzymatic reaction for hydrolysis of FAPGG 
catalyzed by the serum ACE, from the concentration of 
the substrate (Мichaelis-Menten reaction) is presented in 
Fig.1 where the calculated Michaelis constant is 
Km=0.376 mmol/L. The enzymatic kinetic constants were 
calculated using software GraFit v.4 (Eritchacus software 
Limited 2002), and the statistical processing of the 
obtained data was made with Statistica (data analysis 
software system, v.6 StatSoft, Inc. 2001). 
 
Accuracy of the test: Several tests were conducted to test 
the accuracy, the precision and the linearity of the method. 
The precision of the kinetic method was determined with 
serum samples with normal and high ACE activity. The 
enzyme activity for whey samples was determined by the 
kinetic method with substrate FAPGG and commercial 
standard serum containing ACE. 
Procedure of the serum test is described as follows: a) 
in a 2 ml cuvette we poured 1 ml ACE reagent (substrate 
and Tris buffer) and 0.1 ml standard solution of serum 
containing ACE and 0.1 ml water; b) the solutions were 
stirred by flipping the cuvette several times; c) the cuvette 
was placed in an incubator at 37
oC for 45 min; d) after 5 
min, the absorbance was measured and the values for time 
and absorbance were plotted to construct a calibration 
curve for time/absorbance. 
The ACE inhibitory activity of the whey samples was 
determined as follows: In a 2 ml cuvette pour 1 ml ACE 
reagent (substrate and Tris buffer) and 0.1 ml standard 
solution of serum which contained ACE and 0.1 ml water. 
The solutions were stirred by flipping the cuvette several 
times. Then the cuvette was placed in a thermostat at 37
oC 
for 45 min and at an interval of 5 min the value of the 
absorbance was measured. With the values for time and 
absorbance, a calibration curve (time/absorbance) was 
constructed. The ACE inhibitory activity (in %) was 
determined from the calibration curve and calculated by 
the following equation: 
 
 Uninhibited  activity-inhibited  activity 
% inhibition =   ---------------------------------------------- * 100 
 Uninhibited  activity 
(Equation 3) 
 
RESULTS AND DISCUSSION 
 
pH influence and ionic concentration on ACE activity: 
The influence of pH of the buffer solution, concentration 
of chloride ions and the concentration of the substrate 
affecting the activity of ACE in serum, were determined. 
The determination was made by the ACE activity in 
control serum for the range of the Tris buffer from 7.05-
8.95 pH, presented in Table 1. The optimal pH level was 
found to be 8.2. 
The influence of the concentration of chloride ions on 
the activity of ACE were determined using control serum, 
for range of concentrations between 0-0.7 mol/L. The 
results indicated that the optimal concentration of chloride 
ions was 0.30 mol/L. The initial absorbance (A) and 
∆A/min were determined for range of concentrations of 
substrate FAPGG between 0.1-2.0 mol/L, and using 
control serum. The results are presented in Table 2. 
The data presented in figure 1, shows that all ACE 
inhibitory peptides from milk whey as competitive inhibitors, 
directly binds to the active site of enzymes and are 
characterized by unchanged maximal rate of reaction. 
Precision data obtained through testing within and between 
series of samples with normal and high activity of ACE, is 
expressed trough the coefficient of variation  (Table 3). 
The accuracy of the method was tested trough 
determination of the ACE activity in serum samples (92 
U/L and 31 U/L), mixed in different ratios. Results were 
calculated as average three determinations. Table 4 
reports the accuracy of the method for determining the 
ACE activity in serum samples as compared with the 
calculated values. 
The linearity of the method for determining the 
enzymatic activity of ACE in serum samples was tested in 
series of dilutions of control serum with high ACE activity. Pak Vet J, 2013, 33(1): 14-18. 
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Table 1: The effect of Tris buffer pH level on the hydrolysis of 0.8 mmol/L FAPGG catalyzed by ACE (340 nm, 37°C) 
pH level  Dependant variable 
7.05 7.52  7.90  8.18  8.27  8.48 8.60  8.95 
ACE (U/L)*  20  40  50  55  52  46  40  23 
* angiotensin-converting enzyme 
 
Table 2: Effect of the concentration of substrate FAPGG on the initial absorbance and ∆A/min of control serum for ACE (Tris buffer, pH 8, 2; 300 
mmol/L chloride ions) 
Substrate (mmol/L)  Absorbance 
0.1 0.2 0.5  0.8  1.0  1.5  2.0 
Initial  A  0.2248 0.3390 0.6338  0.8809  0.8804  1.3270    1.4497 
∆A/min  0.0006 0.0009 0.0014  0.0018  0.0018  0.0020  0.0021 
 
Table 3: Precision data of the method for ACE activity in serum with 
kinetic method with FAPGG substrate 
Parameter In  series  Between  series 
N 10  10  15  15 
X (U/L)  62  112  58  121 
±SD  20 1.8  2.8  4.8 
CV (%)  3.2   1.8   4.8   4.0  
 
Table 4: Accuracy of the method for determining the ACE activity 
(U/L) in serum samples determined by the test of revealing the 
theoretically calculated data 
Calculated Determined  % Revealing 
61.5  63±1.4 102±2.2 
51  52±0.9 102±1.8 
72  72±1.4   100±1.0 
 
In determining the activity of the enzyme with the method, 
the linear accuracy was to 175 U/L (Fig. 2). 
Whey samples derived from different types of dairy 
products of cows, sheep and mixture of the both in different 
ratios were studied. Total samples were 70 (27 yogurt, 9 sour 
cream, 14 cheese and 20 white cheeses). The mean values 
were worked out. ACE inhibitory activity was reflected in % 
and IC50 (µL) (Table 5). The yogurt and white cheese 
samples presented the highest ACE inhibition, as seen 
descriptive statistics of ACE inhibition in dairy products 
(Table 6). In a pervious study the most effective inhibitors 
were EDTA; CdBr2; angiotensin II; bradykinin; and a 
pentapeptide, L-pyroglutamyl-L-lysyl-L-tryptophyl-L-
alanyl-L-proline, a component of  Bothrops jararaca  venom 
(Cushman and Cheung, 1971).  
It has been noted that all ACE inhibitory peptides from 
dairy products act as competetive inhibitors. There was no 
known correlation between total peptides in whey and in 
vitro ACE inhibitory activity. This notation is in compliance 
with the linear data. 
 
Table 5: Average values of ACE inhibition in the tested dairy products 
 
  In a study, all probiotic yoghurts showed appreciable 
ACE-I activity during initial stages of storage which 
deseased (P<0.05) afterwards (Donkor et al., 2007). The 
ACE-I activity ranged from IC50 of 103.30–27.79 mg 
mL
-1 with the greatest ACE inhibition achieved during 
first and third week of storage. The in vitro ACE-I activity 
could be related to the peptide liberation via degradation 
of caseins. In total, 8 ACE-I peptides were characterized 
originating from αs2-casein, k-casein and β-casein. 
The ACE inhibitory activity was determined in 70 
comercially available samples of dairy products. There 
was a significant variation in the inhibition in different 
products (Fig. 3). This may be the result of origin of 
samples from different production technologies. It was 
noted that ACE inhibitory peptides are most common in 
whey from yogurt and white cheese. 
 
Table 6: Descriptive statistics of ACE inhibition in dairy products 
Type of 
product 
Average 
value 
Standard 
deviation 
Maximum 
value 
Yogurt 36.63  50.5 273 
Sour cream  24.3  11.66  46.6 
White cheese  29.9  14.96  76.4 
Cheese 20.8  12.83  55.8 
 
 
 
Fig. 1: Michaelis-Menten dependence curve of reaction speed of 
FAPGG hydrolysis / concentration of substrate (0.1-3.2 mmol/L; tris 
buffer 50 mmol/L, pH 8.2, t = 37°C) 
 
 
Fig. 2: Linearity of the determination of ACE activity in serum samples 
with the kinetic method and FAPGG substrate. 
 
Chen  et al. (2012) reported a single Val-Ala-Pro 
(VAP) tripeptide in grass carp protein. The tripeptide with 
excellent ACE-inhibitory activity (IC50 value of 0.00534 
mg/mL) was a competitive ACE inhibitor and stable 
against both ACE and gastrointestinal enzymes of pepsin 
Product Inhibition%  Inhibition  IC50 
Yogurt (cow’s milk)  36.6  323.7 
Sour cream (cow’s milk)  28.0  1199.3 
Sour cream (sheep’s milk)  11.4  734.1 
White cheese (cow’s milk)  38.7  162.9 
White cheese (sheep’s milk)  26.9  190.0 
White cheese (goat’s milk)  23.5  212.7 
White cheese (cow’s+sheep’s milk)  18.9  271.5 
Cheese (cow’s milk)  20.8  316.1 Pak Vet J, 2013, 33(1): 14-18. 
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and chymotrypsin. The identified unique biochemical 
properties of VAP may enable the application of grass 
carp protein hydrolysates as a functional food for 
treatments of hypertension. 
 
 
 
Fig. 3: Maximal peaks for ACE inhibition (%) in dairy products. 
Other animal products posses antihypertensive 
properties. Jang and Lee (2005), Saiga et al. (2006) and 
Miguel et al. (2007) reported ACE inhibitory peptides in 
eggs, beef and chicken, respectively. 
A phylogenetic tree constructed with actin sequences 
of both vertebrate and invertebrate species indicated a 
high homology (Vercruysse et al., 2009). Bombyx mor 
was found as a high-potential source of ACE inhibitory 
peptides and this was supported by the ACE inhibitory 
activity of the partially purified actin preparation. It was 
suggested that in food science, in silico analysis can be 
used as fast initial screening tool to look for high-potential 
sources of ACE inhibitory peptides and other peptidic 
bioactivities. 
 
Conclusion:  The  in vitro activity of angiotensin-
converting enzyme was determined with FAPGG 
substrate in whey samples. The method was found as fast, 
simple, specific, free of any interference, having no 
problems regarding the stability of the reagent. The 
method is characterized by good reproducibility and 
accuracy, and also the range of linearity permits detection 
of high ACE activity values. 
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